Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3 rd-generation EGFR inhibitors and outperforms other investigational 4 th-generation inhibitors ...

Jade Biosciences, Inc. announced that new preclinical data on its investigational anti-APRIL monoclonal antibody, JADE101, will be presented at the 62nd European Renal Association Congress in Vienna ...

SAN DIEGO--(BUSINESS WIRE)--Onchilles Pharma, a private biotech company developing pan-cancer therapeutics that leverage the ELANE pathway, a novel innate immune mechanism of action for potent and ...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable ...